EURONEXT-PAR$IPHA

Innate Pharma SA · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

IPHA Q2 2024 — extraction skipped

Innate Pharma SA filed Form 6-K (accession 0001598599-24-000086) for Q2 2024, but headline financial numerics could not be extracted automatically: no headline numerics found by parser nor by Financial Datasets fallback. The row is marked as AI-processed so the queue advances; numerics will be filled by Financial Datasets on its next pass.

  • Form 6-K filed; press release body not parseable here.
  • Reason: no headline numerics found by parser nor by Financial Datasets fallback.
  • Numerics rely on the Financial Datasets fallback.

Headline financials

Total Revenue

$6.64M

Previous: $38.6M-82.8%
EPS (adj)

-$0.16

Previous: $0.02-835.9%
Net Income

-$24.8M

Previous: $1.72M-1541.4%
Operating Income

-$26.3M

Previous: -$5.25M-400.9%
Gross Profit

-$16.7M

Previous: $19.6M-185.3%
R&D Expense

$29.1M

Previous: $28.4M+2.3%

Revenue & EPS history

Innate Pharma SA · Revenue · Quarterly

$6.64M

Q2 2024-82.8%vs Q2 2023
Beat estimate in 3 of 10 quarters(30%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 11 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

-0.6%

Avg return

Earnings day

-0.1%

Avg return

5 days after

-0.2%

Avg return

30 days after

27%

3 / 11 earnings

Positive

+13.5%

Q4 2019

Best reaction

-8.8%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025-2.4%-6.3%-3.1%
Q2 2024-4.2%-2.7%+37.6%
Q4 2023-2.9%+4.3%-1.8%
Q2 2023-3.9%-3.7%-3.0%
Q4 2022-8.8%-10.7%-11.8%
Q2 2022+2.8%+0.7%+13.5%
Q4 2021+2.6%+2.4%-23.3%
Q2 2021-0.6%-1.7%-7.3%
Q4 2020+0.0%+3.2%-5.1%
Q2 2020-2.6%+1.3%-5.1%
Q4 2019+13.5%+11.5%+7.3%
Q2 2019
Q4 2018
Q2 2018
Q4 2017
Q2 2017
Q4 2016
Q2 2016
Q4 2015
Q2 2015
Q4 2014
Q2 2014
Q4 2013
Q2 2013
Q4 2012
Q4 2011
Q2 2011
Q4 2010
Q2 2010

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro